AEON Biopharma, Inc is a cutting-edge biopharmaceutical company based in Irvine, CA, dedicated to harnessing the full potential of therapeutic botulinum toxin. With a focus on neurotoxin research and development, they aim to provide lasting relief to millions of patients suffering from nervous system-related conditions such as migraines and cervical dystonia. Their proprietary botulinum toxin formulation and innovative treatment paradigms offer unique opportunities to healthcare providers and payors.
Operating at the forefront of the field, AEON Biopharma's pipeline includes their lead candidate, ABP-450 prabotulinumtoxinA, which has the potential to significantly improve the lives of individuals living with a range of nerve and muscle-based disorders. With a commitment to science, innovation, and strategic partnerships, AEON Biopharma is poised to unlock new possibilities in therapeutic neurotoxins and make a meaningful impact on patient care.
Generated from the website